Dermata Therapeutics (DRMA) Net Equity Issued and Repurchased (2021 - 2025)
Dermata Therapeutics (DRMA) posted quarterly Net Equity Issued and Repurchased of $4.2 million for Q4 2025, up 6123.75% year-over-year from $67275.3 in Q4 2024, and up 33275.25% quarter-over-quarter from -$12621.0 in Q3 2025.
Dermata Therapeutics (DRMA) Net Equity Issued and Repurchased (2021 - 2025) Analysis & Trends
Dermata Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $4.2 million for Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased rose 6123.75% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $12.2 million (up 216.81% YoY), while the FY2025 annual figure was $12.2 million, up 76.7% from the prior year.
- Net Equity Issued and Repurchased for Q4 2025 stood at $4.2 million, up from -$12621.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $14.8 million in Q4 2021, with the low at -$547857.0 in Q2 2025.
- The 5-year median for Net Equity Issued and Repurchased is $2.0 million (2023), against an average of $3.3 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 6123.75% in 2025, while the deepest fall reached 122.73% in 2025.
- Dermata Therapeutics' Net Equity Issued and Repurchased stood at $14.8 million in 2021, then sank by 71.14% to $4.3 million in 2022, then tumbled by 54.31% to $2.0 million in 2023, then tumbled by 103.56% to -$69509.0 in 2024, then soared by 6123.75% to $4.2 million in 2025.
- Business Quant data shows DRMA's Net Equity Issued and Repurchased at $4.2 million in Q4 2025, -$12621.0 in Q3 2025, and -$547857.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.19 Mn |
| Dec 31, 2025 | 4.19 Mn |
| Sep 30, 2025 | -12,621.00 |
| Sep 30, 2025 | -12,621.00 |
| Jun 30, 2025 | -547,857.00 |
| Jun 30, 2025 | -547,857.00 |
| Mar 31, 2025 | 8.54 Mn |
| Mar 31, 2025 | 8.54 Mn |
| Dec 31, 2024 | -69,509.00 |
| Dec 31, 2024 | -69,509.00 |
| Sep 30, 2024 | 1.50 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 2.41 Mn |
| Jun 30, 2024 | 2.41 Mn |
| Dec 31, 2023 | 1.95 Mn |
| Dec 31, 2023 | 1.95 Mn |
| Sep 30, 2023 | -35,419.00 |
| Sep 30, 2023 | -35,419.00 |
| Jun 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 1.51 Mn |